Baramulla MP Engineer Rashid  (Photo | Express)
India

Delhi HC allows jailed J&K MP Engineer Rashid to attend Parliament in custody

The bench also made it clear that while attending the session, Rashid would not be permitted to use a phone or the internet, nor engage with or address the media.

Shekhar Singh

NEW DELHI: The Delhi High Court has permitted jailed Jammu & Kashmir MP Engineer Rashid to attend the second part of the parliamentary session from March 26 to April 4 while remaining in custody.

A division bench comprising Justice Chandra Dhari Singh and Justice Anup Jairam Bhambhani directed the Director General (Prisons) to ensure Rashid’s transportation from prison to Parliament under police escort during the Lok Sabha’s sitting hours on each of these dates.

The Court ordered that at the Parliament House, the appellant shall be handed over to the custody of Parliament security/marshals, who shall allow the appellant to attend the proceedings of the Lok Sabha and to avail other facilities and amenities within the Parliament House during the hours that the Lok Sabha is in session; and shall thereafter hand-back custody of the appellant to the prison escort, who will bring him back to prison straight from the Parliament House, on the same day, without any delay.

The bench also made it clear that while attending the session, Rashid would not be permitted to use a phone or the internet, nor engage with or address the media. “The appellant shall not interact with any other person, at any time while he is outside the premises of jail, except within the premises of Lok Sabha House,” it ruled.

Why the additional declaration linked to Form 6 is facing a legal challenge

SP-Congress alliance faces fresh strain as Akhilesh skips INDIA bloc meet over UP seat-sharing talks

Rahul Gandhi tells CWC to continue 'resistance' against 'match-fixing' of polls through EVM, voters list

Assam Rifles jawan killed in militant attack in Arunachal; security forces intensify ops to arrest killers

SC slams medicine pricing, calls cancer drug’s 10-fold MRP markup ‘carnage’